Download PDF

1. Company Snapshot

1.a. Company Description

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology.The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine.It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.


The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system.Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial.The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901.


In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies.It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome.VBI Vaccines Inc.


has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants.The company was formerly known as SciVac Therapeutics Inc.and changed its name to VBI Vaccines Inc.


in May 2016.VBI Vaccines Inc.is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on VBIV

{"description": "VBI Vaccines' recent performance was negatively driven by the company's bankruptcy filing, which has raised concerns about its financial stability. The filing is part of the company's ongoing restructuring effort, but it has likely impacted investor confidence. Additionally, the company's focus on pipeline execution, expanding access, and strategic partnerships has not yet translated into significant revenue growth, contributing to the negative sentiment."}

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations

Nov -15

Source: businesswire.com

Card image cap

Why Is VBI Vaccines (VBIV) Stock Up 62% Today?

Aug -06

Source: investorplace.com

Card image cap

VBI Vaccines Announces Results of Annual General Meeting

Jun -25

Source: businesswire.com

Card image cap

VBI Vaccines Reports First Quarter 2024 Financial Results

May -15

Source: businesswire.com

Card image cap

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

Apr -02

Source: businesswire.com

Card image cap

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Feb -14

Source: prnewswire.com

Card image cap

VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern

Sep -27

Source: Market Watch

Card image cap

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

Sep -06

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

License

Expected Growth: 10.47%

The 10.47% growth is driven by increasing demand for vaccines, strategic partnerships, and expanding product pipeline. VBI Vaccines Inc.'s license provides access to innovative vaccine technologies, enhancing its market position. Growing awareness of infectious diseases, government initiatives, and investments in healthcare infrastructure also contribute to the growth.

Vaccines

Expected Growth: 10.47%

VBI Vaccines Inc.'s 10.47% growth is driven by increasing demand for vaccines, successful clinical trials, and strategic partnerships. The company's innovative pipeline, including its coronavirus and hepatitis B vaccine candidates, has attracted significant investments. Additionally, the growing awareness of vaccine importance and government initiatives to improve vaccination rates have contributed to the company's rapid expansion.

Research & Development Service

Expected Growth: 10.27%

VBI Vaccines Inc.'s 10.27% growth in Research & Development Services is driven by increasing demand for vaccine development, strategic partnerships, and investments in novel technologies. The company's focus on infectious disease and cancer vaccine candidates, as well as its expansion into new markets, also contribute to this growth.

7. Detailed Products

VBI-2900

A prophylactic vaccine candidate against cytomegalovirus (CMV) infection

VBI-1501

A therapeutic vaccine candidate against glioblastoma multiforme (GBM)

VBI-1901

A prophylactic vaccine candidate against hepatitis B virus (HBV) infection

VBI-2601

A therapeutic vaccine candidate against coronavirus (COVID-19)

8. VBI Vaccines Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

VBI Vaccines Inc. has a moderate threat of substitutes due to the presence of other vaccine manufacturers and research institutions working on similar vaccine technologies.

Bargaining Power Of Customers

VBI Vaccines Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers and the presence of a large customer base.

Bargaining Power Of Suppliers

VBI Vaccines Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and equipment, but also due to the specialized nature of some of the supplies.

Threat Of New Entrants

VBI Vaccines Inc. has a high threat of new entrants due to the growing demand for vaccines and the increasing interest in vaccine development, which attracts new companies and investors to the market.

Intensity Of Rivalry

VBI Vaccines Inc. operates in a highly competitive market with several established players, which leads to a high intensity of rivalry among companies in the vaccine development and manufacturing industry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 87.57%
Debt Cost 13.34%
Equity Weight 12.43%
Equity Cost 13.34%
WACC 13.34%
Leverage 704.66%

11. Quality Control: VBI Vaccines Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Ginkgo Bioworks

A-Score: 4.3/10

Value: 7.8

Growth: 3.3

Quality: 4.3

Yield: 0.0

Momentum: 9.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
VBI Vaccines

A-Score: 3.9/10

Value: 9.8

Growth: 6.1

Quality: 2.4

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
MeiraGTx

A-Score: 3.8/10

Value: 6.0

Growth: 2.6

Quality: 2.6

Yield: 0.0

Momentum: 9.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Relay Therapeutics

A-Score: 3.6/10

Value: 6.8

Growth: 6.9

Quality: 3.8

Yield: 0.0

Momentum: 2.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
MacroGenics

A-Score: 3.3/10

Value: 8.4

Growth: 6.0

Quality: 3.8

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Lyell Immunopharma

A-Score: 3.2/10

Value: 7.6

Growth: 1.0

Quality: 4.7

Yield: 0.0

Momentum: 5.5

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.07$

Current Price

0.07$

Potential

-0.00%

Expected Cash-Flows